Open access
Open access
Powered by Google Translator Translator

Onco-hematology

RCT | Early oral antibiotic switch in low-risk neutropenic sepsis shows mixed results

3 Aug, 2023 | 13:15h | UTC

Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis (EASI-SWITCH): A randomized non-inferiority trial – Clinical Microbiology and Infection

 


Phase 1 Trial | NI006 shows potential for cardiac amyloid depletion in transthyretin amyloid cardiomyopathy

1 Aug, 2023 | 14:17h | UTC

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial – TCTMD

Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid – American College of cardiology

 


Phase 1–2 study | Liso-cel shows effectiveness against resistant CLL/SLL post BTK inhibitor, venetoclax treatment

20 Jul, 2023 | 10:58h | UTC

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study – The Lancet (link to abstract – $ for full-text)

News Release: Immunotherapy Improves Remission for Relapsed, Refractory Leukemia – Northwestern Medicine

 


Review | Guiding the use of invasive cardiac interventions in patients with advanced malignancies

17 Jul, 2023 | 13:23h | UTC

Invasive Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: A Conceptual Framework: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


Clinical Trial Update | 5-year follow-up validates efficacy of sorafenib maintenance in FLT3-ITD AML

11 Jul, 2023 | 13:37h | UTC

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Single-arm study | Pirtobrutinib exhibits efficacy in CLL patients after failure of covalent BTK inhibitor treatment

7 Jul, 2023 | 16:14h | UTC

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)

News release from the manufacturer: New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma – Lilly

 


Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management

5 Jul, 2023 | 01:00h | UTC

Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management – American Journal of Hematology

 


SR | Polyclonal anti‐thymocyte globulins for the prophylaxis of GVHD after allogeneic stem cell or bone marrow transplantation

3 Jul, 2023 | 14:16h | UTC

Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults – Cochrane Library

Summary: Anti-thymocyte globulins for the prevention of graft-versus-host disease in patients receiving a foreign stem cell transplantation – Cochrane Library

 


RCT | Luspatercept outperforms epoetin alfa in interim analysis, shows promise for lower-risk myelodysplastic syndromes

30 Jun, 2023 | 14:42h | UTC

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial – The Lancet (link to abstract – $ for full-text)

 


RCT | Cyclophosphamide-based regimen enhances GVHD-free survival after hematopoietic stem-cell transplantation

27 Jun, 2023 | 13:54h | UTC

Summary: The article details a phase 3 trial comparing the efficacy of two graft-versus-host disease (GVHD) prophylactic regimens in hematologic cancer patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT). The experimental group received cyclophosphamide–tacrolimus–mycophenolate mofetil, and the standard group received tacrolimus–methotrexate. The patients, a total of 431, underwent HSCT from an HLA-matched related donor or a matched or 7/8 mismatched unrelated donor.

The primary end point was GVHD-free, relapse-free survival at 1 year. Results indicated a significantly higher incidence of this outcome in the experimental group (hazard ratio, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P=0.001). At 1 year, adjusted GVHD-free, relapse-free survival was 52.7% (95% CI, 45.8 to 59.2) in the experimental group, compared to 34.9% (95% CI, 28.6 to 41.3) in the standard group.

Notably, patients in the experimental-prophylaxis group appeared to have less severe acute or chronic GVHD and a higher incidence of immunosuppression-free survival at 1 year. Overall survival, disease-free survival, relapse, transplantation-related death, and engraftment did not show a substantial difference between the groups. These results suggest that cyclophosphamide–tacrolimus–mycophenolate mofetil may offer a more effective prophylaxis against GVHD in HSCT patients.

Article: Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Study Sets New Standard for Graft-Versus-Host Disease Prevention After Stem Cell Transplant – Johns Hopkins Medicine

 

Commentary on Twitter

 


Consensus Paper | Primary prophylaxis of invasive fungal diseases in patients with hematological malignancies

23 Jun, 2023 | 13:23h | UTC

Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) – Journal of Antimicrobial Chemotherapy

 


Consensus Paper | Management of febrile neutropenia in pediatric hematology and oncology patients

20 Jun, 2023 | 12:38h | UTC

Consensus document on the management of febrile neutropenia in paediatric haematology and oncology patients of the Spanish Society of Pediatric Infectious Diseases (SEIP) and the Spanish Society of Pediatric Hematology and Oncology (SEHOP) – Anales de Pediatría

 


Review | Updates in immunohistochemistry for hematopoietic and lymphoid neoplasms

20 Jun, 2023 | 12:36h | UTC

Updates in Immunohistochemistry for Hematopoietic and Lymphoid Neoplasms – Archives of Pathology & Laboratory Medicine

 


RCT | Avapritinib superior to placebo in reducing symptoms, mast-cell burden in indolent systemic mastocytosis patients

20 Jun, 2023 | 12:34h | UTC

Avapritinib versus Placebo in Indolent Systemic Mastocytosis – NEJM Evidence

 

Commentary on Twitter

 


Review | Antifungal stewardship interventions in patients with hematologic malignancies

16 Jun, 2023 | 13:47h | UTC

Antifungal Stewardship Interventions in Patients with Hematologic Malignancies

 


RCT | Second-line treatment with Axi-cel results in increased overall survival in large B-cell lymphoma

14 Jun, 2023 | 14:25h | UTC

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: ASCO: Axi-cel significantly improves survival in patients with early relapsed or refractory large B-cell lymphoma – University of Texas MD Anderson Cancer Center

Commentary: Axicabtagene Ciloleucel Improves Overall Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma – The ASCO Post

 

Commentary on Twitter

 


RCT | Cilta-cel shows superior progression-free survival over standard care in lenalidomide-refractory multiple myeloma

14 Jun, 2023 | 14:22h | UTC

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Findings suggest cilta-cel may be key therapeutic option for patients with multiple myeloma after first relapse – Medical College of Wisconsin

Commentary: CARTITUDE-4 Shows Benefit With Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma – ASCO Daily News

 

Commentary on Twitter

 


Review | Acute graft-versus-host disease

14 Jun, 2023 | 14:20h | UTC

Acute graft-versus-host disease – Nature Reviews Disease Primers (if the link is paywalled, try this one)

 

Commentary on Twitter

 


RCT | Noninferiority shown between DOACs and LMWH for recurrent VTE prevention in cancer patients

5 Jun, 2023 | 13:50h | UTC

Summary: This unblinded, pragmatic, noninferiority randomized clinical trial aimed to assess the efficacy of direct oral anticoagulants (DOACs) against low-molecular-weight heparin (LMWH) in preventing recurrent venous thromboembolism (VTE) in patients with cancer. The study included 671 patients from 67 oncology centers, with a new clinical or radiological diagnosis of VTE.

Participants were randomly assigned to receive either a DOAC or LMWH for 6 months, and treating physicians selected and prescribed the drugs based on considerations like availability and drug-drug interactions. The primary outcome was the rate of recurrent VTE at 6 months. Findings revealed that the DOAC group had a recurrent VTE rate of 6.1% as compared to 8.8% in the LMWH group, showing noninferiority. Both groups had statistically similar rates of major bleeding and severe adverse events.

This pragmatic study included patients with advanced cancer and brain metastases, impaired performance status, and reduced liver or kidney function, making it more representative of routine oncology practice. Moreover, patient adherence to DOAC treatment was significantly higher than to LMWH. Nevertheless, the study had limitations, including the lack of blinding and underrepresentation of certain racial and ethnic groups.

In conclusion, this trial suggests that DOACs were noninferior to LMWH for preventing recurrent VTE in patients with cancer over a 6-month follow-up period, supporting the use of DOACs in this population for VTE prevention. Further research is needed to confirm these results and investigate long-term outcomes.

Article: Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)

See also: Visual abstract

 

Commentary on Twitter

 


Review | Prevention of venous thromboembolism in patients with cancer

5 Jun, 2023 | 13:48h | UTC

Prevention of venous thromboembolism in patients with cancer – The BMJ

 


Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies

1 Jun, 2023 | 11:48h | UTC

Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies – Blood Cancer Journal

 


RCT | Ruxolitinib achieves greater molecular response and EFS in hydroxycarbamide-resistant Polycythemia Vera

22 May, 2023 | 13:35h | UTC

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial – Journal of Clinical Oncology

Commentary: Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype – Cancer Network

 


RCT | Superior progression-free survival with Venetoclax-based regimens in first-line CLL treatment

22 May, 2023 | 13:32h | UTC

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL – The ASCO Post

 

Commentary on Twitter

 


RCT | The addition of Quizartinib to chemotherapy improves overall survival vs placebo in FLT3-ITD-positive AML patients

18 May, 2023 | 13:40h | UTC

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


Phase 2 RCT | Ropeginterferon shows better results in hematocrit control vs phlebotomy alone in patients withr polycythemia vera

18 May, 2023 | 13:37h | UTC

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera – NEJM Evidence

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.